Related Experiment Videos
Virus-like particle and DNA-based candidate AIDS vaccines
Qizhi Yao1, Zhigao Bu, Andrei Vzorov
1Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Vaccine
|January 18, 2003
Summary
Virus-like particles effectively induce cellular and neutralizing antibody responses against HIV infection. Combining these particles with DNA vaccination shows promise for robust anti-HIV immunity, especially at mucosal sites.
Area of Science:
- Immunology
- Virology
- Vaccine Development
Background:
- Humoral and cellular immune responses are crucial for controlling HIV.
- Effective HIV vaccines require induction of both cellular and neutralizing antibody responses.
Purpose of the Study:
- To develop and evaluate virus-like particles (VLPs) as a vaccine platform for HIV.
- To assess the immunogenicity of VLPs, including mucosal administration.
- To explore combination strategies with DNA-based vaccines.
Main Methods:
- Production of HIV and SIV VLPs using a baculovirus expression system.
- Immunization studies evaluating cellular and antibody responses.
- Assessment of mucosal and systemic immune responses following VLP administration.
- Synthesis and evaluation of codon-optimized HIV Env genes.
Main Results:
- VLPs induced significant cellular and neutralizing antibody responses.
- Mucosal administration of VLPs elicited both mucosal and systemic immunity.
- Combination of VLPs with DNA vaccination enhanced anti-HIV immune responses.
Conclusions:
- HIV VLPs are a promising vaccine platform for eliciting anti-viral immunity, particularly neutralizing antibodies.
- Mucosal delivery of VLPs is effective in inducing broad immune responses.
- Combination VLP and DNA vaccination strategies hold potential for effective HIV vaccines.